sustainability-linked instruments

Teva Pharmaceutical Industries has initiated a $2 billion refinancing through euro and dollar-denominated bonds via Dutch subsidiaries to restructure $2 billion in debt maturing between 2026-2031 (including high-coupon sustainability-linked notes). Leveraging current favorable market conditions, the move extends maturities, lowers interest costs, and maintains the parent company’s unconditional guarantees to ensure investor confidence. While introducing modest structural complexity, the strategy aligns with industry-wide debt optimization practices, mirroring recent Big Pharma restructurings.